| Members who responded in 2018 | Eligible members in 2018 | Members who responded in 2020 | Eligible members in 2020 | ||
|---|---|---|---|---|---|
| (n=74) | (n=463) | (n=61) | (n=439) | ||
| n (%) | n (%) | n (%) | n (%) | ||
| Age | ~39 | 9 (12.2%) | 51 (11.0%) | 3 (4.9%) | 51 (11.7%) |
| 40~49 | 10 (13.5%) | 73 (15.8%) | 10 (16.4%) | 69 (15.8%) | |
| 50~59 | 23 (31.1%) | 127 (27.4%) | 22 (36.1%) | 134 (30.7%) | |
| 60~69 | 25 (33.8%) | 99 (21.4%) | 21 (34.4%) | 115 (26.4%) | |
| 70~ | 7 (9.5%) | 50 (10.8%) | 5 (8.2%) | 59 (13.5%) | |
| Unknown | 0 (0.0%) | 63 (13.6%) | 0 (0.0%) | 8 (1.8%) | |
| Sex | Women | 4 (5.4%) | 69 (14.9%) | 3 (5.0%) | 66 (15.1%) |
| Men | 70 (94.6%) | 394 (85.1%) | 58 (95%) | 370 (84.9%) | |
| Specialty | Internal Medicine | 4 (5.4%) | 191 (41.3%) | 7 (11.5%) | 207 (47.5%) |
| Rheumatology | 13 (17.6%) | 45 (9.7%) | 14 (23.0%) | 25 (5.7%) | |
| Nephrology | 17 (23.0%) | 49 (10.6%) | 11 (18.0%) | 47 (10.8%) | |
| Cardiology | 16 (21.6%) | 35 (7.6%) | 14 (23.0%) | 23 (5.3%) | |
| Orthopedic surgery | 6 (8.1%) | 33 (7.1%) | 2 (3.3%) | 28 (6.4%) | |
| Diabetes, Metabolism and Endocrinology | 10 (13.5%) | 32 (6.9%) | 7 (11.5%) | 34 (7.8%) | |
| Hematology and Oncology | 3 (4.1%) | 13 (2.8%) | 3 (5.0%) | 10 (2.3%) | |
| Others | 5 (6.8%) | 65 (14.0%) | 3 (5.0%) | 62 (14.2%) | |
| Affiliation | University | 35 (47.3%) | 198 (42.8%) | 24 (39.3%) | 156 (35.8%) |
| Hospital | 23 (31.1%) | 128 (27.6%) | 24 (39.3%) | 138 (31.7%) | |
| Clinic | 15 (20.3%) | 130 (28.1%) | 13 (21.3%) | 138 (31.7%) | |
| Others | 1 (1.4%) | 7 (1.5%) | 0 (0%) | 4 (0.9%) |
| Items No | Questionnaire of the Use Toward CPG | Agree to ① | Agree to ② | Agree to ③ | Agree to ④ | Agree to ⑤ |
|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | ||
| 1 | Which agent among NSAIDs, glucocorticoids, and colchicine is most favorable for gout flares? ①NSAID, ②glucocorticoid, ③colchicine, ④three agents are equal, ⑤I do not know. | 31 (50.8) | 3 (4.9) | 8 (13.1) | 14 (23.0) | 5 (8.2) |
| Items No | Questionnaire of the Use of and Attitudes Toward CPG | Strongly agree and Agree groups | Disagree, Strongly disagree, and Other groups | |||
| Number (%) | Number (%) | |||||
| 2 | Do you use ULA to preserve renal function in hyperuricemic patients with kidney disease? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 53 (86.9) | 8 (13.1) | |||
| 3 | Do you use ULA to improve patient prognosis and reduce the cardiovascular event risk in hyperuricemic patients with hypertension? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 27 (44.3) | 34 (55.7) | |||
| 4 | Is your target serum urate level for treating gout patients with tophi less than 6 mg/dl? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 57 (93.4) | 4 (6.6) | |||
| 5 | Do you use ULA to improve the patient’s prognosis in hyperuricemic patients with heart failure? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 23 (37.7) | 38 (62.3) | |||
| 6 | Do you use colchicine coverage to prevent recurrence of gout flares in gout patients when initiating ULA? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 33 (54.1) | 28 (45.9) | |||
| 7 | Do you provide dietary education to asymptomatic hyperuricemic patients? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 42 (68.9) | 19 (31.1) | |||
| 8 | Do you use the guidelines for the management and treatment of hyperuricemia and gout in your daily practice? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 53 (86.9) | 8 (13.1) | |||
| 9 | Do you find the recommendations for CQ 1 to 7 useful in your daily practice? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 55 (90.2) | 6 (9.8) | |||
| 10 | Did this guideline help you identify a theme for your clinical research or an important clinical issue for future CQs? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 49 (80.3) | 12 (19.7) | |||
| Items No | Questionnaire on the Use of and Attitudes Toward CPG | Strongly agree and Agree groups (%) | Disagree, Strongly disagree, and Other groups (%) |
|---|---|---|---|
| 11 | Are the algorithms of this guideline comprehensive? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 56 (91.8) | 5 (8.2) |
| 12 | Did you change your therapeutic approach after using this guideline? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 41(67.2) | 20 (32.8) |
| 13 | Did you gain more confidence in the treatment of hyperuricemia and gout after using this guideline? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 45 (73.8) | 16 (26.2) |
| 14 | Do you use this guideline to inform your decision-making with patients? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 43 (70.5) | 18 (29.5) |
| 15 | Do you think this guideline may restrict the discretion of the physician? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 15 (24.6) | 46 (75.4) |
| 16 | Do you use this guideline for educating medical students and medical interns? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 31 (50.8) | 30 (49.2) |
| 17 | Do you use this guideline to communicate with medical staff? ①strongly agree, ②agree, ③disagree, ④strongly disagree, ⑤ I do not know. | 28 (45.9) | 33 (54.1) |
